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A B S T R A C T
Background: No data exists regarding the uptake of inﬂuenza vaccination in patients with heart failure
(HF) in India. The present study was designed to assess the uptake, knowledge, attitude and practices of
the Indian HF patients towards inﬂuenza vaccination.
Methods and results: Five-hundred patients with acute/chronic HF were approached for a personal
interview and responses to an interview recorded in a pre-deﬁned questionnaire depicting their
knowledge, attitudes and practice regarding inﬂuenza vaccination. Of the 500 approached, 320 (64%,
174 male, age 3–90 years) consented to participate in the survey. Only 7.5% (n = 24) knew of inﬂuenza as
an illness with adverse potential consequences for themselves or their family. Seventeen (5.3%) were
aware of potentially serious nature of inﬂuenza and 40 (12.5%) knew of the availability of a vaccine
against it and its local availability. However only 14 (4.4%) had actually received the vaccine 1–2 times in
the past 5 years. Only 21 (6.56%) had been prescribed inﬂuenza vaccine by their respective physicians.
Reasons for declining vaccination included misperceptions about safety and efﬁcacy of the vaccine. Most
of the participants, however, had not been prescribed vaccination at all.
Conclusions: Poor inﬂuenza vaccination rates in HF mandate intense efforts to improve vaccination rates.
 2016 Published by Elsevier B.V. on behalf of Cardiological Society of India. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Inﬂuenza is a major cause of morbidity and mortality in high
risk populations like those with chronic medical conditions.1,2
Patients with heart failure (HF) are at a higher risk of hospitaliza-
tion in the inﬂuenza season compared to the non-inﬂuenza
season3,4 with winter peaking of the cardiovascular events being
attributed to the inﬂuenza viral infection as against the earlier
attribution to cold weather.5 Of adults hospitalized during the
2013–2014 inﬂuenza season, the most commonly-occurring
chronic condition was heart disease, found in 37% of these.6
The European Society of Cardiology has recommended inﬂuenza
vaccination and included it in the treatment guidelines for acute and
chronic HF as an essential topic of patient education.7 Annual
vaccination has been recommended by the American Heart
Association and the American College of Cardiology since 2006,
as a secondary preventive measure for cardiovascular morbidity and
all-cause mortality.7 However the rate of inﬂuenza vaccination in
patients with cardiovascular disease (CVD) is very low, and even
lower in those with long-term disease.8,9 Only 1 in every 3 adults* Corresponding author at: Department of Internal & Pulmonary Medicine, Sher I
Kashmir Institute of Medical Sciences, Soura, Srinagar 190011, J&K, India. URL:
http://www.skims.ac.in
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creativecommons.org/licenses/by-nc-nd/4.0/).with heart disease in USA (34%) received inﬂuenza vaccination in
2010, a level of coverage that was essentially unchanged from other
below-target rates achieved in 2002.10 In 2005, vaccination coverage
among elderly in USA (65 years old) with heart disease was found to
be much higher (71%) than among middle-aged (50–64 years old)
and younger (18–49 years old) adults with heart disease (41% and
23%, respectively).10 A major roadblock to vaccination against
inﬂuenza in the US is that only about one half of cardiology practices
in USA stock inﬂuenza vaccine, as opposed to 70% of endocrinology
and primary care practices and 90% of pulmonology practices.11,12
There is a paucity of literature on the uptake of inﬂuenza
vaccination in the Indian subcontinent in high risk groups and no
data are available on patients with HF. We have previously
reported that healthcare workers (HCWs) have a number of
misperceptions about inﬂuenza vaccination13 and their prescrib-
ing practices to high risk groups like diabetics,14 pregnant
females,15 and COPD patients16 are inadequate. The present study
has been designed to study the uptake of inﬂuenza vaccine among
patients with HF, as also assess their knowledge and attitudes
towards inﬂuenza vaccination.
2. Methods
The study was conducted in a tertiary care hospital in north
India, where seasonal inﬂuenza has been reported with a in north Indian patients with heart failure, Indian Heart J. (2016),
 India. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Questionnaire for Survey of Inﬂuenza vaccination in CCF.
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on an assumed true proportion of 10% of an inﬁnite population, a
precision of +0.05 and a conﬁdence level of 0.95, the sample size
arrived at was 139. We randomly screened 500 patients
diagnosed with HF (acute/chronic), of whom 320 (64%)
consented for participation. The participants were interviewed
and the responses recorded in a predeﬁned and validated
questionnaire. The questionnaire (Table 1) consisted of 21 ques-
tions which included demographic information, knowledge,
attitudes and practices regarding inﬂuenza vaccination and
perceptions about inﬂuenza. Responses were also requested
about vaccination site and information that the participants
desired about inﬂuenza vaccination and their preferred mode of
reaching out to them. The questionnaire was administered by
one of the investigators who are working in the Inﬂuenza
laboratory of the hospital and apart from having participated in
similar surveys previously were trained speciﬁcally for the
study. They spoke the same dialect as that of the participating
patients. The responses recorded were analyzed using descrip-
tive statistics of the recorded variables (Statistical Package for
Social Sciences, version 17). Informed consent was obtained
from all participants and the survey was approved by the
Institute Ethics Committee.
3. Results
The 320 consenting participants consisted of 146 male and
174 female patients, either currently admitted with HF or seen
during a post-discharge follow-up visit. The age of the patients
ranged from 3 years to 90 years; 60% (n = 191) being 60 years.
Only 3 (0.93%) patients were younger than 18 years of age whereas
26 (8.12%) belonged to the 18–39 year age group and 100 (31.25%)
to the 40–59 year group. Two-hundred forty-six patients were
from rural setting whereas the rest were from urban setting.
Various co-morbidities included COPD (n = 87, 27.2%), hyperten-
sion (n = 54, 16.9%), community-acquired pneumonia (CAP)
(n = 35, 10.9%), type 2 diabetes mellitus (n = 39, 12.2%), and dilated
cardiomyopathy (n = 13, 4.1%).
Only 7.5% (n = 24) of the participants considered inﬂuenza as an
illness with adverse potential consequences for themselves or their
family. Seventeen (5.3%) were aware of its potentially serious
nature and 40 (12.5%) knew of the availability of a vaccine against
inﬂuenza and its local availability. However only 14 (4.4%) had
received the vaccine 1–2 times in the past 5 years, >70% of those
vaccinated being >60 years of age (Table 2). None of the
participants aged <40 years had received the vaccine twenty-
one (6.56%) of the participants had been prescribed inﬂuenza
vaccine by their respective physicians but only 14 complied
receiving the vaccine in hospitals 4(28.57%), private clinics 6
(42.85%) or through family doctors 4 (28.57%). The 7 declining
vaccination despite prescription possessed concerns about vaccine
safety, believing it to be capable of causing immune and other
system disorders. Others who did not receive vaccination were not
aware of the seriousness of inﬂuenza and some responded that
they did not have time for vaccination. However, most (n = 292) of
the patients had not been advised vaccination by their respective
physicians.
The participants expressed a desire for convenient dissemina-
tion of information regarding various aspects of inﬂuenza
vaccination including current year’s vaccine, difference between
common cold and ﬂu, safety and adverse effects of vaccination.
Most of them desired that the information be circulated through
various means of technology ranging from radio (41.87%), SMS via
mobile phones (26.25%), print newsletter (24.68%) or electronic
mail (7.18%).Please cite this article in press as: Koul PA, et al. Inﬂuenza vaccination
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Our data suggest a poor vaccination uptake in Indian patients
with HF. The study, to the best of our knowledge, is the ﬁrst study
that addresses this aspect of patients with HF in the Indian
subcontinent. The practices of the physicians and the patients
across other areas of the subcontinent need to be studied in order
to ascertain if the data are extrapolatable to other areas of the
subcontinent.
Most of the vaccinated participants in the current study were
aged 60 years or above (Table 2). A higher vaccination uptake has in north Indian patients with heart failure, Indian Heart J. (2016),
Table 2
Distribution of the participants in various age groups and the vaccination rates.
Columns 2 and 3 depict number and percentages of the total vaccinated and
unvaccinated participants whereas column 4 depicted the number and percentage
rates in different age groups.
Age group Vaccinated
(n = 14)
N (%)
Non-vaccinated
(n = 306)
N (%)
Total
vaccinated of
the age group
N (%)
<18 years 0 (0) 3 (1) 0 (0)
18–39 years 0 (0) 26 (8.5) 0 (0)
40–59 years 4 (28.6) 96 (31.4) 4 (4)
60 years 10 (71.4) 181 (59.2) 10 (5.2)
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Bittner et al.18 This age group constitutes a high risk group for
complications related to inﬂuenza and is a high priority for
vaccination. Additionally, frequent presence of other comorbidities
in them encompasses them as a high-risk group for inﬂuenza,
independent of the presence of HF. The effects of socioeconomic
factors and educational status could not be ascertained as the
number of recipients of vaccination was very low and most (n = 10)
of them were aged >60 years and were uneducated.
The beneﬁts of inﬂuenza vaccination in CVD are not clearly
deﬁned. In a recent Cochrane review of 8 studies involving 12,029
participants receiving at least one vaccination or control treat-
ment, the authors concluded that the data did not provide enough
information to show the effectiveness of inﬂuenza vaccination in
the primary prevention of fatal or non-fatal cardiovascular events.
However, in patients with established CVD, evidence suggested
that inﬂuenza vaccination may reduce cardiovascular mortality
and combined cardiovascular events.19 In another recent study, a
lower risk of hospitalization for acute coronary syndrome (ACS)
was observed among patient with COPD receiving inﬂuenza
vaccination. Similar protective effect regardless of inﬂuenza
seasonality was observed in both sexes and all age groups.20 In
yet another prospective population-based cohort involving
1964 participants with acute HF, inﬂuenza vaccination was
associated with improved survival in acute HF.21 The beneﬁts of
vaccination against inﬂuenza are not restricted to prevention of
decompensation of cardiac failure due to respiratory infections.
Vaccination has been related to other events, such as the primary
and secondary prevention of coronary events, reduction of
cerebrovascular accidents, reduced hospitalizations and costs for
other diseases, especially among the elderly.17,22,23
The mechanisms underlying the cardiovascular protective
effect of inﬂuenza vaccine are poorly understood. One current
hypothesis states that the inﬂammatory response of the body to
inﬂuenza viral infection produces autoantibodies to modiﬁed low-
density lipoprotein, thus developing and progressing atheroscle-
rotic vascular injury, while another hypothesis postulates the
initiation and perpetuation of inﬂammatory response by activation
of antigen presenting cells by local colonization of vessel wall.24
Using informational spectrum method, Velijkovic et al. identiﬁed
bradykinin 2 receptor (BKB2R) as a principal host protein that
could mediate molecular processes underlying the cardioprotec-
tive effect of inﬂuenza vaccines. They suggested that some
antibodies elicited by inﬂuenza vaccines act as agonists, which
activate a BKB2R-associated signalling pathway contributing to
the protection against CVD.21 Patients with HF mount a lower
antibody response upon vaccination and the antibody titres to
inﬂuenza A vaccine strains wane to below seroprotective levels in
HF patients compared with healthy controls, despite similar rates
of initial seroprotection and seroconversion. These ﬁndings
suggest that HF patients may remain at increased risk for inﬂuenza
infection despite annual vaccination25 and cautiously mightPlease cite this article in press as: Koul PA, et al. Inﬂuenza vaccination
http://dx.doi.org/10.1016/j.ihj.2016.07.012suggest the possible role of high dose ﬂu vaccine or a twice
annually schedule of vaccination. Both of these approaches need to
be studied for comparative immunogenicity so that recommenda-
tions can be based on more robust scientiﬁc evidence.
Our study is limited by the fact that it was conducted in a
tertiary care setting and the results may not be possible to be
extrapolated to other primary and secondary care settings.
However we believe that the level of awareness and uptake of
vaccination is likely to be even lower in those settings. Nonetheless
further studies in those settings would give a complete picture and
need to be conducted on priority. With its diverse geography and
socio-cultural practices, the knowledge, attitudes and practices
regarding vaccination could exhibit signiﬁcant dispersion which
needs study. Another limitation of the study is that the knowledge,
attitudes and practices of the caregivers was not assessed.
However our recent data suggest that there is inadequate
knowledge about inﬂuenza vaccination among healthcare work-
ers, there are misperceptions about safety and there is a disconnect
between perceptions and practice.13
In conclusion, vaccination uptake in Indian patients with HF is
poor, rooted primarily in inadequate prescription practices by
healthcare providers who thus require sensitization regarding
vaccination efﬁcacy and safety. Measures aimed at increasing the
uptake need urgently to be put in place.
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